Nohla Announces EHA Abstract Acceptance on Dilanubicel

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
50
Nohla Announces EHA Abstract Acceptance on Dilanubicel (NLA101) Off-the-Shelf Cell Therapy Showing Excellent Long-term Survival Outcomes

SEATTLE, May 17, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the online availability of an abstract that has been selected for presentation during the 23 rd Congress of European Hematology Association Annual Conference in Stockholm. The abstract is available at https://learningcenter.ehaweb.org/eha/2018/st...74*media=3 and a copy of the poster will be available on the Company’s website after it has been presented.

The abstract summarizes long-term follow-up data showing that Nohla’s dilanubicel (NLA101) cell therapy significantly improved hematopoietic recovery with no patients experiencing transplant-related mortality, leading to an 86% (n=13/15) disease-free and overall survival rate in patients undergoing a cord blood transplant. Patient survival rates were evaluated at five years following transplant.

“Allogeneic hematopoietic cell transplantation remains the only known curative approach for patients with high-risk leukemia, however access is limited by donor availability,” said Filippo Milano, MD, PhD, Assistant Member at Fred Hutchinson Cancer Research Center’s Clinical Research Division and Associate Director of its Cord Blood Program. “Umbilical cord blood has emerged as an important source of donor stem cells but adoption has been limited due to the low number of cells contained in each graft.  Results to date show that dilanubicel may address this need by providing expanded stem and progenitor cells resulting in rapid immune recovery and long-term survival benefits compared to standard cord blood transplant and other allogeneic transplants.”

“These results demonstrate that infusion of dilanubicel given with a cord blood transplant was safe and led to faster neutrophil and platelet recovery, but more importantly showed excellent long-term survival with no transplant-related mortality or severe (grade 3-4) acute graft vs. host disease,” said Colleen Delaney, MD, MSc, Chief Medical Officer and Co-founder of Nohla Therapeutics. “We expect to have top-line results later this year from Nohla’s ongoing randomized Phase 2b trial coordinated by the Fred Hutch evaluating dilanubicel in 160 patients with hematologic malignancies receiving a cord blood transplant.”

   
Title:  Non-HLA Matched, Ex-Vivo Expanded Cord Blood Product Significantly Improves the
  Kinetics of Hematopoietic Recovery and Results in Excellent Survival in Patients
  Undergoing Cord Blood Transplantation
Session Title:  Stem Cell Transplantation - Clinical
Session Date:  Friday, June 15, 5:30 – 7:00 PM CEST
Location:  Stockholm, Sweden
Abstract Code:  PF728
   

About Dilanubicel Dilanubicel is a universal donor, off-the-shelf, ex vivo expanded hematopoietic stem and progenitor cell product that provides rapid, transient hematopoiesis with long-term immunologic benefits. Unlike autologous or patient-specific allogeneic cell therapies, dilanubicel does not require Human Leukocyte Antigen (HLA) tissue matching. Intentionally developed to provide short-term, temporary bone marrow function until a patient’s immune system recovers, dilanubicel also induces long-term immunologic benefits with the potential for improved survival. Dilanubicel is efficiently manufactured ahead of time, cryopreserved, and available for immediate off-the-shelf use.

About Nohla Therapeutics Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla’s proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company’s lead product candidate, dilanubicel, is currently being evaluated in two ongoing Phase 2 trials for patients with hematologic malignancies undergoing a myeloablative allogeneic transplant, and acute myeloid leukemia (AML) patients with chemotherapy-induced myelosuppression following high-dose chemotherapy.  Nohla is also pursuing multiple preclinical and discovery programs in the areas of immune tolerance and other diseases. More information is available at www.nohlatherapeutics.com .

Nohla Contact: Jim DeNike Senior Director, Corporate Development & Investor Relations 206.519.5294 jimd@nohlatherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 394

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 278

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 181

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 194

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 137

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 201

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 202

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

FarmHouse Fresh Celebrates 20 Years of Skincare Innovation

Updated Category News Views 294

Celebrating Two Decades of Skincare Excellence FarmHouse Fresh® is excited to celebrate its 20th anniversary, a significant milestone in its journey of transforming skincare routines and enriching lives through animal rescue. Over the last two decades, the brand has become renowned for its unique farm-to-table skincare products, drawing inspiration from nature's best...

Continue Reading
Rigetti Computing and Quanta Computer Join Forces for Quantum Advancements

Updated Category News Views 437

Exciting Collaboration in Quantum Technology Rigetti Computing, Inc. (NASDAQ: RGTI), a leader in quantum-classical computing, has forged a powerful collaboration with Quanta Computer Inc., a major player based in Taiwan. This strategic agreement signifies a strong commitment from both companies to push the boundaries of superconducting quantum computing, with a shared...

Continue Reading
Crucial Update for Match Group, Inc. Investors: Act Now

Updated Category News Views 189

Update on Match Group, Inc.'s Ongoing Class Action In recent developments, investors holding shares in Match Group, Inc. (NASDAQ: MTCH) are reminded of their rights as a class action has been initiated on behalf of those who purchased or acquired MTCH securities during the designated period. This lawsuit follows significant stockholder losses, particularly pertaining to...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 214

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Stock Market Movements: Energy Surges as Instil Bio Drops

Updated Category News Views 144

Stock Market Overview The latest trading session produced varied results for U.S. stocks, creating a mixed bag for investors. The Nasdaq Composite dipped by about 1%. In contrast, the Dow Jones Industrial Average rose by 0.29%, reaching a noteworthy 41,512.19. On the other hand, the S&P 500 experienced a slight decline of 0.24%, settling at 5,612.35. Sector Performance...

Continue Reading